Creative BioMart to Present at
                        BIO-Europe Spring Creative BioMart to Present at AACR Annual Meeting|Apr. 5-10, 2024|Booth #2953

Recombinant Human BACE1 protein

Cat.No. : BACE1-003H
Product Overview : Recombinant Human BACE1 (Thr22-Thr457) protein carried no tag and was expressed in human 293 cells (HEK293).
  • Specification
  • Gene Information
  • Related Products
Description : Beta-secretase 1 (BACE1) is also known as beta-site APP cleaving enzyme 1 (beta-site amyloid precursor protein cleaving enzyme 1), memapsin-2 (membrane-associated aspartic protease 2), and aspartyl protease 2 (ASP2), β-Secretase, and is a member of the peptidase A1 protein family, BACE1 is a type I integral membrane glycoprotein and aspartic protease that is found mainly in the Golgi. BACE1 is an aspartic-acid protease important in the pathogenesis of Alzheimer's disease, and in the formation of myelin sheaths in peripheral nerve cells. The transmembrane protein contains two active site aspartate residues in its extracellular protein domain and may function as a dimer. This protease is responsible for the proteolytic processing of the amyloid precursor protein (APP). Generation of the 40 or 42 amino acid-long amyloid-β peptides that aggregate in the brain of Alzheimer's patients requires two sequential cleavages of the APP. Extracellular cleavage of APP by BACE creates a soluble extracellular fragment and a cell membrane-bound fragment referred to as C99. The elevation of BACE1 levels can be induced by amyloid plaques surrounding neurons at early stages of pathology before neuron death occurs, and may drive a positive-feedback loop in AD.
Source : HEK293
Species : Human
Predicted N Terminal : Thr22
Form : Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 20 mM CaCl2, pH8.0, 10% trehalose.
Molecular Mass : The protein has a calculated MW of 49.0 kDa. The protein migrates as 53-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Protein length : Thr22-Thr457
Endotoxin : Less than 1.0 EU per μg by the LAL method.
Purity : >98% as determined by SDS-PAGE.
Storage : For long term storage, the product should be stored at lyophilized state at -20 centigrade or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20 to -70 centigrade for 12 months in lyophilized state;
-70 centigrade for 3 months under sterile conditions after reconstitution.
Reconstitution : It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents.
Gene Name : BACE1
Official Symbol : BACE1
Synonyms : BACE1; beta-site APP-cleaving enzyme 1; BACE, beta site APP cleaving enzyme; beta-secretase 1; asp 2; memapsin-2; APP beta-secretase; aspartyl protease 2; beta-site APP cleaving enzyme 1; beta-secretase 1 precursor variant 1; transmembrane aspartic proteinase Asp2; membrane-associated aspartic protease 2; beta-site amyloid beta A4 precursor protein-cleaving enzyme; ASP2; BACE; HSPC104; FLJ90568; KIAA1149
Gene ID : 23621
mRNA Refseq : NM_001207048
Protein Refseq : NP_001193977
MIM : 604252
UniProt ID : P56817

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (5)

Ask a question
Are there any potential side effects associated with BACE1 inhibition? 08/20/2021

Yes, several clinical trials are underway to assess the safety and efficacy of BACE1 inhibitors in treating Alzheimer's disease.

How is BACE1 linked to Alzheimer's disease? 01/05/2020

BACE1 is implicated in Alzheimer's disease as it initiates the cleavage of APP, leading to the formation of beta-amyloid plaques, a hallmark of the disease.

How can BACE1 inhibitors potentially benefit Alzheimer's patients? 08/11/2018

BACE1 inhibitors may slow down or prevent the accumulation of beta-amyloid plaques, potentially delaying the progression of Alzheimer's disease.

Are there any ongoing clinical trials involving BACE1 inhibitors? 09/22/2017

Yes, several clinical trials are underway to assess the safety and efficacy of BACE1 inhibitors in treating Alzheimer's disease.

Are there clinical applications of BACE1 inhibitors? 08/07/2016

Yes, BACE1 inhibitors are being explored as potential therapeutic agents for Alzheimer's disease to reduce the production of beta-amyloid peptides.

Customer Reviews (3)

Write a review
Reviews
07/27/2020

    Such support ensures researchers have access to reliable tools and expertise, facilitating their investigations into the functions, mechanisms, and disease relevance of BACE1 protein.

    12/23/2019

      A manufacturer can serve as a collaborative partner, engaging in discussions, and exchanging knowledge with researchers.

      09/30/2019

        Using BACE1 protein in trials provides advantages such as its involvement in cellular processes and its disease associations.

        Ask a Question for All BACE1 Products

        Required fields are marked with *

        My Review for All BACE1 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /

        Stay Updated on the Latest Bioscience Trends